Pharma’s R&D pipeline is its lifeblood. The industry-wide pipeline is today worth a staggering $1.4 trillion. Yet, like many others, you may find that getting R&D priorities right remains a real challenge. Decade-long development timelines, new technologies, regulatory hurdles, an ever-changing competitive landscape and budget conscious payers all need to be taken into account when building and maintaining a healthy pipeline.
In this article we look at the questions you need to ask to make sure that you’re investing in the right assets.
